nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxazosin—hypertension—type 2 diabetes mellitus	0.426	1	CtDrD
Doxazosin—ADRA2A—type 2 diabetes mellitus	0.155	1	CbGaD
Doxazosin—ORM1—Nateglinide—type 2 diabetes mellitus	0.0312	0.118	CbGbCtD
Doxazosin—ADRA1D—Bromocriptine—type 2 diabetes mellitus	0.0294	0.112	CbGbCtD
Doxazosin—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0214	0.0813	CbGbCtD
Doxazosin—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0176	0.0669	CbGbCtD
Doxazosin—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0169	0.0642	CbGbCtD
Doxazosin—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0141	0.0534	CbGbCtD
Doxazosin—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.0132	0.0501	CbGbCtD
Doxazosin—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0125	0.0476	CbGbCtD
Doxazosin—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.0112	0.0426	CbGbCtD
Doxazosin—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.0112	0.0426	CbGbCtD
Doxazosin—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.0104	0.0393	CbGbCtD
Doxazosin—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.01	0.038	CbGbCtD
Doxazosin—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00906	0.0344	CbGbCtD
Doxazosin—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00853	0.0324	CbGbCtD
Doxazosin—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00787	0.0299	CbGbCtD
Doxazosin—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00647	0.0246	CbGbCtD
Doxazosin—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00622	0.0236	CbGbCtD
Doxazosin—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0062	0.0235	CbGbCtD
Doxazosin—CYP2C19—Glyburide—type 2 diabetes mellitus	0.00575	0.0218	CbGbCtD
Doxazosin—CYP2C19—Losartan—type 2 diabetes mellitus	0.00525	0.02	CbGbCtD
Doxazosin—ABCB1—Glyburide—type 2 diabetes mellitus	0.00464	0.0176	CbGbCtD
Doxazosin—ABCB1—Losartan—type 2 diabetes mellitus	0.00424	0.0161	CbGbCtD
Doxazosin—Prazosin—ADRA2A—type 2 diabetes mellitus	0.00039	0.41	CrCbGaD
Doxazosin—Alfuzosin—CYP3A4—type 2 diabetes mellitus	0.000299	0.315	CrCbGaD
Doxazosin—Donepezil—CYP3A4—type 2 diabetes mellitus	0.000261	0.275	CrCbGaD
Doxazosin—Hypertension—Irbesartan—type 2 diabetes mellitus	4.28e-05	0.000399	CcSEcCtD
Doxazosin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	4.27e-05	0.000399	CcSEcCtD
Doxazosin—Flushing—Ramipril—type 2 diabetes mellitus	4.27e-05	0.000398	CcSEcCtD
Doxazosin—Infection—Metformin—type 2 diabetes mellitus	4.26e-05	0.000397	CcSEcCtD
Doxazosin—Insomnia—Valsartan—type 2 diabetes mellitus	4.26e-05	0.000397	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	4.24e-05	0.000395	CcSEcCtD
Doxazosin—Paraesthesia—Valsartan—type 2 diabetes mellitus	4.23e-05	0.000394	CcSEcCtD
Doxazosin—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	4.23e-05	0.000394	CcSEcCtD
Doxazosin—Myalgia—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000394	CcSEcCtD
Doxazosin—Chest pain—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000394	CcSEcCtD
Doxazosin—Arthralgia—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000394	CcSEcCtD
Doxazosin—Shock—Metformin—type 2 diabetes mellitus	4.22e-05	0.000394	CcSEcCtD
Doxazosin—Insomnia—Orlistat—type 2 diabetes mellitus	4.21e-05	0.000393	CcSEcCtD
Doxazosin—Malaise—Losartan—type 2 diabetes mellitus	4.21e-05	0.000393	CcSEcCtD
Doxazosin—Anxiety—Irbesartan—type 2 diabetes mellitus	4.21e-05	0.000392	CcSEcCtD
Doxazosin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	4.21e-05	0.000392	CcSEcCtD
Doxazosin—Thrombocytopenia—Metformin—type 2 diabetes mellitus	4.2e-05	0.000392	CcSEcCtD
Doxazosin—Dyspnoea—Valsartan—type 2 diabetes mellitus	4.2e-05	0.000392	CcSEcCtD
Doxazosin—Vertigo—Losartan—type 2 diabetes mellitus	4.19e-05	0.000391	CcSEcCtD
Doxazosin—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4.19e-05	0.000391	CcSEcCtD
Doxazosin—Somnolence—Valsartan—type 2 diabetes mellitus	4.19e-05	0.000391	CcSEcCtD
Doxazosin—Syncope—Losartan—type 2 diabetes mellitus	4.19e-05	0.00039	CcSEcCtD
Doxazosin—Paraesthesia—Orlistat—type 2 diabetes mellitus	4.18e-05	0.00039	CcSEcCtD
Doxazosin—Leukopenia—Losartan—type 2 diabetes mellitus	4.18e-05	0.00039	CcSEcCtD
Doxazosin—Discomfort—Irbesartan—type 2 diabetes mellitus	4.17e-05	0.000389	CcSEcCtD
Doxazosin—Skin disorder—Metformin—type 2 diabetes mellitus	4.17e-05	0.000389	CcSEcCtD
Doxazosin—Hyperhidrosis—Metformin—type 2 diabetes mellitus	4.15e-05	0.000387	CcSEcCtD
Doxazosin—Dyspepsia—Valsartan—type 2 diabetes mellitus	4.15e-05	0.000387	CcSEcCtD
Doxazosin—Dizziness—Bromocriptine—type 2 diabetes mellitus	4.13e-05	0.000385	CcSEcCtD
Doxazosin—Dry mouth—Irbesartan—type 2 diabetes mellitus	4.13e-05	0.000385	CcSEcCtD
Doxazosin—Palpitations—Losartan—type 2 diabetes mellitus	4.13e-05	0.000385	CcSEcCtD
Doxazosin—Nausea—Glimepiride—type 2 diabetes mellitus	4.11e-05	0.000384	CcSEcCtD
Doxazosin—Arrhythmia—Ramipril—type 2 diabetes mellitus	4.11e-05	0.000383	CcSEcCtD
Doxazosin—Loss of consciousness—Losartan—type 2 diabetes mellitus	4.1e-05	0.000383	CcSEcCtD
Doxazosin—Nausea—Sitagliptin—type 2 diabetes mellitus	4.1e-05	0.000382	CcSEcCtD
Doxazosin—Dyspepsia—Orlistat—type 2 diabetes mellitus	4.1e-05	0.000382	CcSEcCtD
Doxazosin—Asthenia—Glyburide—type 2 diabetes mellitus	4.1e-05	0.000382	CcSEcCtD
Doxazosin—Decreased appetite—Valsartan—type 2 diabetes mellitus	4.1e-05	0.000382	CcSEcCtD
Doxazosin—Anorexia—Metformin—type 2 diabetes mellitus	4.09e-05	0.000381	CcSEcCtD
Doxazosin—Cough—Losartan—type 2 diabetes mellitus	4.07e-05	0.00038	CcSEcCtD
Doxazosin—Urticaria—Gliclazide—type 2 diabetes mellitus	4.07e-05	0.00038	CcSEcCtD
Doxazosin—Alopecia—Ramipril—type 2 diabetes mellitus	4.06e-05	0.000379	CcSEcCtD
Doxazosin—Fatigue—Valsartan—type 2 diabetes mellitus	4.06e-05	0.000379	CcSEcCtD
Doxazosin—Body temperature increased—Gliclazide—type 2 diabetes mellitus	4.05e-05	0.000378	CcSEcCtD
Doxazosin—Abdominal pain—Gliclazide—type 2 diabetes mellitus	4.05e-05	0.000378	CcSEcCtD
Doxazosin—Oedema—Irbesartan—type 2 diabetes mellitus	4.05e-05	0.000378	CcSEcCtD
Doxazosin—Decreased appetite—Orlistat—type 2 diabetes mellitus	4.05e-05	0.000377	CcSEcCtD
Doxazosin—Pruritus—Glyburide—type 2 diabetes mellitus	4.04e-05	0.000377	CcSEcCtD
Doxazosin—Mental disorder—Ramipril—type 2 diabetes mellitus	4.03e-05	0.000376	CcSEcCtD
Doxazosin—Constipation—Valsartan—type 2 diabetes mellitus	4.03e-05	0.000376	CcSEcCtD
Doxazosin—Infection—Irbesartan—type 2 diabetes mellitus	4.02e-05	0.000375	CcSEcCtD
Doxazosin—Fatigue—Orlistat—type 2 diabetes mellitus	4.01e-05	0.000374	CcSEcCtD
Doxazosin—Hypotension—Metformin—type 2 diabetes mellitus	4.01e-05	0.000374	CcSEcCtD
Doxazosin—Malnutrition—Ramipril—type 2 diabetes mellitus	4e-05	0.000373	CcSEcCtD
Doxazosin—Shock—Irbesartan—type 2 diabetes mellitus	3.98e-05	0.000371	CcSEcCtD
Doxazosin—Pain—Orlistat—type 2 diabetes mellitus	3.98e-05	0.000371	CcSEcCtD
Doxazosin—Chest pain—Losartan—type 2 diabetes mellitus	3.97e-05	0.000371	CcSEcCtD
Doxazosin—Myalgia—Losartan—type 2 diabetes mellitus	3.97e-05	0.000371	CcSEcCtD
Doxazosin—Arthralgia—Losartan—type 2 diabetes mellitus	3.97e-05	0.000371	CcSEcCtD
Doxazosin—Vomiting—Bromocriptine—type 2 diabetes mellitus	3.97e-05	0.00037	CcSEcCtD
Doxazosin—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	3.96e-05	0.00037	CcSEcCtD
Doxazosin—Anxiety—Losartan—type 2 diabetes mellitus	3.96e-05	0.000369	CcSEcCtD
Doxazosin—Tachycardia—Irbesartan—type 2 diabetes mellitus	3.95e-05	0.000368	CcSEcCtD
Doxazosin—Rash—Bromocriptine—type 2 diabetes mellitus	3.94e-05	0.000367	CcSEcCtD
Doxazosin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.93e-05	0.000367	CcSEcCtD
Doxazosin—Skin disorder—Irbesartan—type 2 diabetes mellitus	3.93e-05	0.000367	CcSEcCtD
Doxazosin—Tension—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000366	CcSEcCtD
Doxazosin—Discomfort—Losartan—type 2 diabetes mellitus	3.93e-05	0.000366	CcSEcCtD
Doxazosin—Dysgeusia—Ramipril—type 2 diabetes mellitus	3.92e-05	0.000366	CcSEcCtD
Doxazosin—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	3.91e-05	0.000365	CcSEcCtD
Doxazosin—Headache—Bromocriptine—type 2 diabetes mellitus	3.91e-05	0.000365	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	3.91e-05	0.000364	CcSEcCtD
Doxazosin—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.91e-05	0.000364	CcSEcCtD
Doxazosin—Nervousness—Ramipril—type 2 diabetes mellitus	3.89e-05	0.000363	CcSEcCtD
Doxazosin—Dry mouth—Losartan—type 2 diabetes mellitus	3.89e-05	0.000362	CcSEcCtD
Doxazosin—Anorexia—Irbesartan—type 2 diabetes mellitus	3.86e-05	0.00036	CcSEcCtD
Doxazosin—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.85e-05	0.000359	CcSEcCtD
Doxazosin—Paraesthesia—Metformin—type 2 diabetes mellitus	3.85e-05	0.000359	CcSEcCtD
Doxazosin—Muscle spasms—Ramipril—type 2 diabetes mellitus	3.85e-05	0.000359	CcSEcCtD
Doxazosin—Confusional state—Losartan—type 2 diabetes mellitus	3.84e-05	0.000358	CcSEcCtD
Doxazosin—Feeling abnormal—Orlistat—type 2 diabetes mellitus	3.84e-05	0.000358	CcSEcCtD
Doxazosin—Dyspnoea—Metformin—type 2 diabetes mellitus	3.82e-05	0.000357	CcSEcCtD
Doxazosin—Somnolence—Metformin—type 2 diabetes mellitus	3.81e-05	0.000356	CcSEcCtD
Doxazosin—Oedema—Losartan—type 2 diabetes mellitus	3.81e-05	0.000355	CcSEcCtD
Doxazosin—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.81e-05	0.000355	CcSEcCtD
Doxazosin—Infection—Losartan—type 2 diabetes mellitus	3.79e-05	0.000353	CcSEcCtD
Doxazosin—Hypotension—Irbesartan—type 2 diabetes mellitus	3.78e-05	0.000353	CcSEcCtD
Doxazosin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	3.78e-05	0.000352	CcSEcCtD
Doxazosin—Dyspepsia—Metformin—type 2 diabetes mellitus	3.78e-05	0.000352	CcSEcCtD
Doxazosin—Tremor—Ramipril—type 2 diabetes mellitus	3.75e-05	0.00035	CcSEcCtD
Doxazosin—Shock—Losartan—type 2 diabetes mellitus	3.75e-05	0.00035	CcSEcCtD
Doxazosin—Urticaria—Valsartan—type 2 diabetes mellitus	3.74e-05	0.000349	CcSEcCtD
Doxazosin—Thrombocytopenia—Losartan—type 2 diabetes mellitus	3.73e-05	0.000348	CcSEcCtD
Doxazosin—Decreased appetite—Metformin—type 2 diabetes mellitus	3.73e-05	0.000348	CcSEcCtD
Doxazosin—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.72e-05	0.000347	CcSEcCtD
Doxazosin—Tachycardia—Losartan—type 2 diabetes mellitus	3.72e-05	0.000347	CcSEcCtD
Doxazosin—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000346	CcSEcCtD
Doxazosin—Nausea—Bromocriptine—type 2 diabetes mellitus	3.71e-05	0.000346	CcSEcCtD
Doxazosin—Fatigue—Metformin—type 2 diabetes mellitus	3.7e-05	0.000345	CcSEcCtD
Doxazosin—Urticaria—Orlistat—type 2 diabetes mellitus	3.7e-05	0.000345	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	3.69e-05	0.000344	CcSEcCtD
Doxazosin—Hyperhidrosis—Losartan—type 2 diabetes mellitus	3.68e-05	0.000343	CcSEcCtD
Doxazosin—Body temperature increased—Orlistat—type 2 diabetes mellitus	3.68e-05	0.000343	CcSEcCtD
Doxazosin—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.68e-05	0.000343	CcSEcCtD
Doxazosin—Asthenia—Gliclazide—type 2 diabetes mellitus	3.68e-05	0.000343	CcSEcCtD
Doxazosin—Agitation—Ramipril—type 2 diabetes mellitus	3.68e-05	0.000343	CcSEcCtD
Doxazosin—Constipation—Metformin—type 2 diabetes mellitus	3.67e-05	0.000342	CcSEcCtD
Doxazosin—Paraesthesia—Irbesartan—type 2 diabetes mellitus	3.64e-05	0.000339	CcSEcCtD
Doxazosin—Anorexia—Losartan—type 2 diabetes mellitus	3.63e-05	0.000339	CcSEcCtD
Doxazosin—Vomiting—Glyburide—type 2 diabetes mellitus	3.63e-05	0.000339	CcSEcCtD
Doxazosin—Pruritus—Gliclazide—type 2 diabetes mellitus	3.63e-05	0.000338	CcSEcCtD
Doxazosin—Malaise—Ramipril—type 2 diabetes mellitus	3.61e-05	0.000337	CcSEcCtD
Doxazosin—Dyspnoea—Irbesartan—type 2 diabetes mellitus	3.61e-05	0.000337	CcSEcCtD
Doxazosin—Rash—Glyburide—type 2 diabetes mellitus	3.6e-05	0.000336	CcSEcCtD
Doxazosin—Somnolence—Irbesartan—type 2 diabetes mellitus	3.6e-05	0.000336	CcSEcCtD
Doxazosin—Dermatitis—Glyburide—type 2 diabetes mellitus	3.6e-05	0.000335	CcSEcCtD
Doxazosin—Vertigo—Ramipril—type 2 diabetes mellitus	3.6e-05	0.000335	CcSEcCtD
Doxazosin—Syncope—Ramipril—type 2 diabetes mellitus	3.59e-05	0.000335	CcSEcCtD
Doxazosin—Leukopenia—Ramipril—type 2 diabetes mellitus	3.58e-05	0.000334	CcSEcCtD
Doxazosin—Headache—Glyburide—type 2 diabetes mellitus	3.58e-05	0.000334	CcSEcCtD
Doxazosin—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.56e-05	0.000332	CcSEcCtD
Doxazosin—Hypotension—Losartan—type 2 diabetes mellitus	3.56e-05	0.000332	CcSEcCtD
Doxazosin—Palpitations—Ramipril—type 2 diabetes mellitus	3.54e-05	0.00033	CcSEcCtD
Doxazosin—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.54e-05	0.00033	CcSEcCtD
Doxazosin—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.52e-05	0.000328	CcSEcCtD
Doxazosin—Loss of consciousness—Ramipril—type 2 diabetes mellitus	3.52e-05	0.000328	CcSEcCtD
Doxazosin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.51e-05	0.000327	CcSEcCtD
Doxazosin—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.51e-05	0.000327	CcSEcCtD
Doxazosin—Cough—Ramipril—type 2 diabetes mellitus	3.49e-05	0.000326	CcSEcCtD
Doxazosin—Fatigue—Irbesartan—type 2 diabetes mellitus	3.49e-05	0.000325	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.47e-05	0.000324	CcSEcCtD
Doxazosin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.47e-05	0.000324	CcSEcCtD
Doxazosin—Convulsion—Ramipril—type 2 diabetes mellitus	3.47e-05	0.000323	CcSEcCtD
Doxazosin—Constipation—Irbesartan—type 2 diabetes mellitus	3.46e-05	0.000323	CcSEcCtD
Doxazosin—Pain—Irbesartan—type 2 diabetes mellitus	3.46e-05	0.000323	CcSEcCtD
Doxazosin—Insomnia—Losartan—type 2 diabetes mellitus	3.45e-05	0.000321	CcSEcCtD
Doxazosin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.43e-05	0.00032	CcSEcCtD
Doxazosin—Paraesthesia—Losartan—type 2 diabetes mellitus	3.42e-05	0.000319	CcSEcCtD
Doxazosin—Urticaria—Metformin—type 2 diabetes mellitus	3.41e-05	0.000318	CcSEcCtD
Doxazosin—Arthralgia—Ramipril—type 2 diabetes mellitus	3.41e-05	0.000318	CcSEcCtD
Doxazosin—Myalgia—Ramipril—type 2 diabetes mellitus	3.41e-05	0.000318	CcSEcCtD
Doxazosin—Chest pain—Ramipril—type 2 diabetes mellitus	3.41e-05	0.000318	CcSEcCtD
Doxazosin—Dyspnoea—Losartan—type 2 diabetes mellitus	3.4e-05	0.000317	CcSEcCtD
Doxazosin—Anxiety—Ramipril—type 2 diabetes mellitus	3.4e-05	0.000317	CcSEcCtD
Doxazosin—Nausea—Glyburide—type 2 diabetes mellitus	3.39e-05	0.000316	CcSEcCtD
Doxazosin—Abdominal pain—Metformin—type 2 diabetes mellitus	3.39e-05	0.000316	CcSEcCtD
Doxazosin—Dizziness—Gliclazide—type 2 diabetes mellitus	3.39e-05	0.000316	CcSEcCtD
Doxazosin—Somnolence—Losartan—type 2 diabetes mellitus	3.39e-05	0.000316	CcSEcCtD
Doxazosin—Asthenia—Valsartan—type 2 diabetes mellitus	3.38e-05	0.000315	CcSEcCtD
Doxazosin—Discomfort—Ramipril—type 2 diabetes mellitus	3.37e-05	0.000314	CcSEcCtD
Doxazosin—Dyspepsia—Losartan—type 2 diabetes mellitus	3.35e-05	0.000313	CcSEcCtD
Doxazosin—Asthenia—Orlistat—type 2 diabetes mellitus	3.34e-05	0.000311	CcSEcCtD
Doxazosin—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.34e-05	0.000311	CcSEcCtD
Doxazosin—Pruritus—Valsartan—type 2 diabetes mellitus	3.33e-05	0.000311	CcSEcCtD
Doxazosin—Dry mouth—Ramipril—type 2 diabetes mellitus	3.33e-05	0.000311	CcSEcCtD
Doxazosin—Decreased appetite—Losartan—type 2 diabetes mellitus	3.31e-05	0.000309	CcSEcCtD
Doxazosin—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.31e-05	0.000309	CcSEcCtD
Doxazosin—Confusional state—Ramipril—type 2 diabetes mellitus	3.29e-05	0.000307	CcSEcCtD
Doxazosin—Pruritus—Orlistat—type 2 diabetes mellitus	3.29e-05	0.000307	CcSEcCtD
Doxazosin—Fatigue—Losartan—type 2 diabetes mellitus	3.28e-05	0.000306	CcSEcCtD
Doxazosin—Oedema—Ramipril—type 2 diabetes mellitus	3.27e-05	0.000305	CcSEcCtD
Doxazosin—Vomiting—Gliclazide—type 2 diabetes mellitus	3.26e-05	0.000304	CcSEcCtD
Doxazosin—Constipation—Losartan—type 2 diabetes mellitus	3.26e-05	0.000304	CcSEcCtD
Doxazosin—Pain—Losartan—type 2 diabetes mellitus	3.26e-05	0.000304	CcSEcCtD
Doxazosin—Rash—Gliclazide—type 2 diabetes mellitus	3.23e-05	0.000301	CcSEcCtD
Doxazosin—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.23e-05	0.000301	CcSEcCtD
Doxazosin—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.22e-05	0.000301	CcSEcCtD
Doxazosin—Urticaria—Irbesartan—type 2 diabetes mellitus	3.22e-05	0.0003	CcSEcCtD
Doxazosin—Shock—Ramipril—type 2 diabetes mellitus	3.21e-05	0.0003	CcSEcCtD
Doxazosin—Headache—Gliclazide—type 2 diabetes mellitus	3.21e-05	0.0003	CcSEcCtD
Doxazosin—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.2e-05	0.000298	CcSEcCtD
Doxazosin—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.2e-05	0.000298	CcSEcCtD
Doxazosin—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	3.2e-05	0.000298	CcSEcCtD
Doxazosin—Tachycardia—Ramipril—type 2 diabetes mellitus	3.19e-05	0.000297	CcSEcCtD
Doxazosin—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.18e-05	0.000297	CcSEcCtD
Doxazosin—Skin disorder—Ramipril—type 2 diabetes mellitus	3.17e-05	0.000296	CcSEcCtD
Doxazosin—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	3.16e-05	0.000295	CcSEcCtD
Doxazosin—Feeling abnormal—Losartan—type 2 diabetes mellitus	3.14e-05	0.000293	CcSEcCtD
Doxazosin—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	3.12e-05	0.000291	CcSEcCtD
Doxazosin—Dizziness—Valsartan—type 2 diabetes mellitus	3.12e-05	0.00029	CcSEcCtD
Doxazosin—Anorexia—Ramipril—type 2 diabetes mellitus	3.11e-05	0.00029	CcSEcCtD
Doxazosin—Dizziness—Orlistat—type 2 diabetes mellitus	3.08e-05	0.000287	CcSEcCtD
Doxazosin—Asthenia—Metformin—type 2 diabetes mellitus	3.08e-05	0.000287	CcSEcCtD
Doxazosin—Hypotension—Ramipril—type 2 diabetes mellitus	3.05e-05	0.000285	CcSEcCtD
Doxazosin—Nausea—Gliclazide—type 2 diabetes mellitus	3.05e-05	0.000284	CcSEcCtD
Doxazosin—Pruritus—Metformin—type 2 diabetes mellitus	3.04e-05	0.000283	CcSEcCtD
Doxazosin—Urticaria—Losartan—type 2 diabetes mellitus	3.03e-05	0.000282	CcSEcCtD
Doxazosin—Abdominal pain—Losartan—type 2 diabetes mellitus	3.01e-05	0.000281	CcSEcCtD
Doxazosin—Body temperature increased—Losartan—type 2 diabetes mellitus	3.01e-05	0.000281	CcSEcCtD
Doxazosin—Vomiting—Valsartan—type 2 diabetes mellitus	3e-05	0.000279	CcSEcCtD
Doxazosin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	2.98e-05	0.000278	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	2.98e-05	0.000278	CcSEcCtD
Doxazosin—Rash—Valsartan—type 2 diabetes mellitus	2.97e-05	0.000277	CcSEcCtD
Doxazosin—Dermatitis—Valsartan—type 2 diabetes mellitus	2.97e-05	0.000277	CcSEcCtD
Doxazosin—Vomiting—Orlistat—type 2 diabetes mellitus	2.96e-05	0.000276	CcSEcCtD
Doxazosin—Insomnia—Ramipril—type 2 diabetes mellitus	2.95e-05	0.000276	CcSEcCtD
Doxazosin—Headache—Valsartan—type 2 diabetes mellitus	2.95e-05	0.000275	CcSEcCtD
Doxazosin—Diarrhoea—Metformin—type 2 diabetes mellitus	2.94e-05	0.000274	CcSEcCtD
Doxazosin—Rash—Orlistat—type 2 diabetes mellitus	2.94e-05	0.000274	CcSEcCtD
Doxazosin—Paraesthesia—Ramipril—type 2 diabetes mellitus	2.93e-05	0.000274	CcSEcCtD
Doxazosin—Dermatitis—Orlistat—type 2 diabetes mellitus	2.93e-05	0.000273	CcSEcCtD
Doxazosin—Headache—Orlistat—type 2 diabetes mellitus	2.92e-05	0.000272	CcSEcCtD
Doxazosin—Dyspnoea—Ramipril—type 2 diabetes mellitus	2.91e-05	0.000272	CcSEcCtD
Doxazosin—Asthenia—Irbesartan—type 2 diabetes mellitus	2.9e-05	0.000271	CcSEcCtD
Doxazosin—Somnolence—Ramipril—type 2 diabetes mellitus	2.9e-05	0.000271	CcSEcCtD
Doxazosin—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.88e-05	0.000268	CcSEcCtD
Doxazosin—Pruritus—Irbesartan—type 2 diabetes mellitus	2.86e-05	0.000267	CcSEcCtD
Doxazosin—Decreased appetite—Ramipril—type 2 diabetes mellitus	2.84e-05	0.000265	CcSEcCtD
Doxazosin—Dizziness—Metformin—type 2 diabetes mellitus	2.84e-05	0.000265	CcSEcCtD
Doxazosin—Fatigue—Ramipril—type 2 diabetes mellitus	2.82e-05	0.000263	CcSEcCtD
Doxazosin—Hypersensitivity—Losartan—type 2 diabetes mellitus	2.81e-05	0.000262	CcSEcCtD
Doxazosin—Nausea—Valsartan—type 2 diabetes mellitus	2.8e-05	0.000261	CcSEcCtD
Doxazosin—Constipation—Ramipril—type 2 diabetes mellitus	2.79e-05	0.000261	CcSEcCtD
Doxazosin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.77e-05	0.000258	CcSEcCtD
Doxazosin—Nausea—Orlistat—type 2 diabetes mellitus	2.76e-05	0.000258	CcSEcCtD
Doxazosin—Asthenia—Losartan—type 2 diabetes mellitus	2.73e-05	0.000255	CcSEcCtD
Doxazosin—Vomiting—Metformin—type 2 diabetes mellitus	2.73e-05	0.000254	CcSEcCtD
Doxazosin—Rash—Metformin—type 2 diabetes mellitus	2.7e-05	0.000252	CcSEcCtD
Doxazosin—Dermatitis—Metformin—type 2 diabetes mellitus	2.7e-05	0.000252	CcSEcCtD
Doxazosin—Pruritus—Losartan—type 2 diabetes mellitus	2.7e-05	0.000251	CcSEcCtD
Doxazosin—Feeling abnormal—Ramipril—type 2 diabetes mellitus	2.69e-05	0.000251	CcSEcCtD
Doxazosin—Headache—Metformin—type 2 diabetes mellitus	2.69e-05	0.000251	CcSEcCtD
Doxazosin—Dizziness—Irbesartan—type 2 diabetes mellitus	2.68e-05	0.00025	CcSEcCtD
Doxazosin—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.67e-05	0.000249	CcSEcCtD
Doxazosin—Diarrhoea—Losartan—type 2 diabetes mellitus	2.61e-05	0.000243	CcSEcCtD
Doxazosin—Urticaria—Ramipril—type 2 diabetes mellitus	2.6e-05	0.000242	CcSEcCtD
Doxazosin—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.58e-05	0.000241	CcSEcCtD
Doxazosin—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.58e-05	0.000241	CcSEcCtD
Doxazosin—Vomiting—Irbesartan—type 2 diabetes mellitus	2.57e-05	0.00024	CcSEcCtD
Doxazosin—Rash—Irbesartan—type 2 diabetes mellitus	2.55e-05	0.000238	CcSEcCtD
Doxazosin—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.55e-05	0.000238	CcSEcCtD
Doxazosin—Nausea—Metformin—type 2 diabetes mellitus	2.55e-05	0.000238	CcSEcCtD
Doxazosin—Headache—Irbesartan—type 2 diabetes mellitus	2.54e-05	0.000237	CcSEcCtD
Doxazosin—Dizziness—Losartan—type 2 diabetes mellitus	2.52e-05	0.000235	CcSEcCtD
Doxazosin—Vomiting—Losartan—type 2 diabetes mellitus	2.42e-05	0.000226	CcSEcCtD
Doxazosin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.41e-05	0.000224	CcSEcCtD
Doxazosin—Nausea—Irbesartan—type 2 diabetes mellitus	2.4e-05	0.000224	CcSEcCtD
Doxazosin—Rash—Losartan—type 2 diabetes mellitus	2.4e-05	0.000224	CcSEcCtD
Doxazosin—Dermatitis—Losartan—type 2 diabetes mellitus	2.4e-05	0.000224	CcSEcCtD
Doxazosin—Headache—Losartan—type 2 diabetes mellitus	2.39e-05	0.000223	CcSEcCtD
Doxazosin—Asthenia—Ramipril—type 2 diabetes mellitus	2.34e-05	0.000219	CcSEcCtD
Doxazosin—Pruritus—Ramipril—type 2 diabetes mellitus	2.31e-05	0.000216	CcSEcCtD
Doxazosin—Nausea—Losartan—type 2 diabetes mellitus	2.26e-05	0.000211	CcSEcCtD
Doxazosin—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.24e-05	0.000208	CcSEcCtD
Doxazosin—Dizziness—Ramipril—type 2 diabetes mellitus	2.16e-05	0.000201	CcSEcCtD
Doxazosin—Vomiting—Ramipril—type 2 diabetes mellitus	2.08e-05	0.000194	CcSEcCtD
Doxazosin—Rash—Ramipril—type 2 diabetes mellitus	2.06e-05	0.000192	CcSEcCtD
Doxazosin—Dermatitis—Ramipril—type 2 diabetes mellitus	2.06e-05	0.000192	CcSEcCtD
Doxazosin—Headache—Ramipril—type 2 diabetes mellitus	2.05e-05	0.000191	CcSEcCtD
Doxazosin—Nausea—Ramipril—type 2 diabetes mellitus	1.94e-05	0.000181	CcSEcCtD
Doxazosin—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	2.8e-06	5.85e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.8e-06	5.85e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CYP2E1—type 2 diabetes mellitus	2.79e-06	5.82e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.78e-06	5.81e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	2.78e-06	5.81e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	2.76e-06	5.76e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—SLC2A1—type 2 diabetes mellitus	2.75e-06	5.75e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CYP1A2—type 2 diabetes mellitus	2.75e-06	5.75e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	2.75e-06	5.75e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.75e-06	5.74e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	2.74e-06	5.73e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.73e-06	5.7e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	2.73e-06	5.69e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	2.72e-06	5.68e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.71e-06	5.67e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.71e-06	5.67e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	2.69e-06	5.62e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	2.69e-06	5.62e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.69e-06	5.61e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CYP3A4—type 2 diabetes mellitus	2.69e-06	5.61e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	2.67e-06	5.58e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.67e-06	5.58e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—C3—type 2 diabetes mellitus	2.67e-06	5.57e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	2.67e-06	5.57e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	2.65e-06	5.54e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.65e-06	5.54e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—SLC2A4—type 2 diabetes mellitus	2.64e-06	5.52e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—GCG—type 2 diabetes mellitus	2.64e-06	5.52e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.64e-06	5.51e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	2.63e-06	5.5e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	2.63e-06	5.5e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.63e-06	5.49e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	2.62e-06	5.48e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.6e-06	5.43e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	2.58e-06	5.4e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	2.58e-06	5.39e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	2.58e-06	5.39e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.58e-06	5.38e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	2.56e-06	5.35e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	2.56e-06	5.35e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—INS—type 2 diabetes mellitus	2.56e-06	5.34e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.55e-06	5.33e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.54e-06	5.32e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.54e-06	5.3e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—AGT—type 2 diabetes mellitus	2.54e-06	5.3e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	2.53e-06	5.29e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	2.53e-06	5.29e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.52e-06	5.27e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.52e-06	5.26e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	2.5e-06	5.23e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.49e-06	5.21e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—APOE—type 2 diabetes mellitus	2.48e-06	5.19e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—LEP—type 2 diabetes mellitus	2.48e-06	5.19e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.47e-06	5.17e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.47e-06	5.16e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	2.47e-06	5.16e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.47e-06	5.16e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.46e-06	5.14e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	2.46e-06	5.14e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.46e-06	5.13e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	2.45e-06	5.12e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	2.45e-06	5.11e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	2.43e-06	5.07e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	2.43e-06	5.07e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.43e-06	5.07e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	2.42e-06	5.06e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.39e-06	5e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	2.37e-06	4.95e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.35e-06	4.91e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.34e-06	4.89e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.29e-06	4.79e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	2.28e-06	4.76e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.28e-06	4.76e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	2.27e-06	4.73e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.26e-06	4.72e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.25e-06	4.71e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.25e-06	4.71e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	2.25e-06	4.7e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.24e-06	4.68e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.24e-06	4.68e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	2.24e-06	4.67e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.22e-06	4.64e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	2.22e-06	4.64e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.22e-06	4.63e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.21e-06	4.63e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.21e-06	4.62e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	2.21e-06	4.61e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	2.21e-06	4.61e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	2.2e-06	4.6e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.18e-06	4.56e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.18e-06	4.56e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	2.17e-06	4.53e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	2.14e-06	4.46e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—INS—type 2 diabetes mellitus	2.12e-06	4.43e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	2.12e-06	4.43e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	2.11e-06	4.41e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—RELA—type 2 diabetes mellitus	2.11e-06	4.41e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.1e-06	4.39e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.09e-06	4.38e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	2.09e-06	4.38e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.09e-06	4.37e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	2.09e-06	4.37e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	2.09e-06	4.37e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.09e-06	4.36e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	2.08e-06	4.35e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	2.08e-06	4.35e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.08e-06	4.35e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	2.07e-06	4.33e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.06e-06	4.31e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.06e-06	4.3e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	2.06e-06	4.3e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.05e-06	4.29e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.05e-06	4.29e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	2.05e-06	4.28e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	2.05e-06	4.28e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.04e-06	4.27e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	2.03e-06	4.24e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.03e-06	4.23e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.02e-06	4.23e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	2.02e-06	4.22e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	2e-06	4.17e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.98e-06	4.14e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.97e-06	4.12e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	1.97e-06	4.11e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.97e-06	4.11e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.95e-06	4.07e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	1.94e-06	4.06e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.94e-06	4.06e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.93e-06	4.04e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.92e-06	4.02e-05	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.92e-06	4.01e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	1.92e-06	4.01e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.91e-06	3.98e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.9e-06	3.98e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.9e-06	3.96e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.89e-06	3.95e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	1.88e-06	3.94e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.87e-06	3.9e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	1.87e-06	3.9e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.86e-06	3.89e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.86e-06	3.89e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.86e-06	3.89e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.85e-06	3.87e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	1.84e-06	3.84e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	1.84e-06	3.84e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	1.83e-06	3.82e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.83e-06	3.82e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.82e-06	3.81e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.82e-06	3.81e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.82e-06	3.8e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.81e-06	3.79e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.81e-06	3.78e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.8e-06	3.76e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.79e-06	3.74e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.79e-06	3.73e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.78e-06	3.72e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	1.77e-06	3.7e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.75e-06	3.66e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.75e-06	3.66e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.74e-06	3.65e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	1.74e-06	3.64e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	1.74e-06	3.63e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.73e-06	3.62e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.73e-06	3.62e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.72e-06	3.6e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	1.72e-06	3.59e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.72e-06	3.59e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.7e-06	3.55e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.7e-06	3.54e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.69e-06	3.54e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.69e-06	3.54e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.69e-06	3.52e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.68e-06	3.52e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	1.68e-06	3.51e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.68e-06	3.5e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—SRC—type 2 diabetes mellitus	1.66e-06	3.47e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.65e-06	3.45e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.65e-06	3.45e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.63e-06	3.41e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.62e-06	3.37e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.61e-06	3.36e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.6e-06	3.35e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.6e-06	3.34e-05	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.59e-06	3.33e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.58e-06	3.3e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.58e-06	3.3e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.57e-06	3.28e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.56e-06	3.25e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.54e-06	3.21e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.54e-06	3.21e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	1.51e-06	3.16e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.49e-06	3.12e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	1.48e-06	3.1e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.48e-06	3.1e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.48e-06	3.09e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.48e-06	3.09e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.45e-06	3.04e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.45e-06	3.03e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.45e-06	3.03e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.45e-06	3.02e-05	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.42e-06	2.96e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.4e-06	2.93e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.39e-06	2.91e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.39e-06	2.91e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.38e-06	2.88e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.36e-06	2.85e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	1.36e-06	2.84e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.34e-06	2.8e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.33e-06	2.77e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.33e-06	2.77e-05	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.32e-06	2.75e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.31e-06	2.74e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.3e-06	2.72e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	1.3e-06	2.72e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	1.3e-06	2.72e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.3e-06	2.71e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.29e-06	2.69e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.27e-06	2.65e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.27e-06	2.65e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.25e-06	2.61e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.23e-06	2.57e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.23e-06	2.57e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.22e-06	2.55e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.22e-06	2.55e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.21e-06	2.52e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.2e-06	2.5e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.2e-06	2.5e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.2e-06	2.5e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.19e-06	2.49e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	1.19e-06	2.49e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.16e-06	2.43e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.14e-06	2.37e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—IL6—type 2 diabetes mellitus	1.12e-06	2.33e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.11e-06	2.31e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.09e-06	2.29e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.09e-06	2.28e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.07e-06	2.24e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.03e-06	2.15e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.02e-06	2.12e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.96e-07	2.08e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	9.27e-07	1.94e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.55e-07	1.79e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	8.44e-07	1.76e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	8.24e-07	1.72e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	7.65e-07	1.6e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.6e-07	1.59e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.06e-07	1.48e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	5.98e-07	1.25e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	5.84e-07	1.22e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	5.5e-07	1.15e-05	CbGpPWpGaD
